INVESTOR ALERT!





LATEST BREAKING NEWS


Martin Nutraceuticals Inc. Opens Negotiations
to Enter the Australian Market


RENO, Nevada - March 26, 2007 - Martin Nutraceuticals Inc. (OTCPK: MNCL) is pleased to announce that it entered into negotiations with JPS Trading Co., a company focused on distribution of supplements and natural products in Australia.


JPS Trading Co. will represent all of Martin's flagship products, Arthrizyme, Oxygenol and Maximum Slim, and will also represent Dr. Martin's book, Medical Crisis - Secrets Your Doctor Won't Share With You. The marketing strategy by JPS will focus on mass distribution of Martin's flagship ingestible products into major retail and supplement centers. The strategy of marketing of the book will follow the North American model and will be sold through a direct sales DRTV (infomercial) campaign.

"This could be a fantastic opportunity for Martin Nutraceuticals," states Harvey Panesar, President of Martin Nutraceuticals Inc., "We are very excited about the possibilities of entering the Australian market, which is an absolute bonus since we have been focusing on getting our infomercial/DRTV campaign to air in North America. We were not actively searching for other markets outside of North America, but when this opportunity arose, we could not turn it down - it just made sense to at least explore where it could lead."


IT IS ESTIMATED THAT IN THE UNITED STATES, THAT NEARLY
10% OF THE POPULATION IS SUFFERING FROM SOME SORT OF JOINT PAIN.

IT IS ALSO ESTIMATED THAT OVER 20 MILLION AMERICANS, MOSTLY OVER THE AGE OF 45 HAVE OSTEOARTHRITIS.


The Australian market size for nutraceuticals has been consistently rising over the last few years. The current market size for nutraceuticals in Australia has exceeded over $900 million; largely due in part to 60% of the Australian population currently using a nutraceutical product, which equivocates to 7.5 million Australian consumers. Source: Aztec Information System





COMPANY PROFILE






In 1989, The Foundation for Innovation in Medicine coined the term "nutraceutical" to give identity to a highly promising area of health and medicine. Since then, the nutraceutical market has become a highly respected industry for supplement health, averaging a 7% increase year over year for the last 5 years.

Martin Nutraceuticals was a natural progression that started from the inception of bettering the lifestyle of people. Since, Martin Nutraceuticals has created a family of complimentary medicine and supplementation that has helped thousands of people suffering from arthritis and general joint pain, poor circulation, tiredness, obesity and digestive complications.

By integrating proprietary oral systemic enzymes, Martin Nutraceuticals has revolutionized the consumption of naturopathic supplementation. With the use of these enzymes with products such as ArthrizymeTM , Martin Nutraceuticals has designed an innovative way to treat arthritis and general joint pain.

Martin Nutraceuticals’ family of natural supplementation also includes Heartzyme™ , Digestzyme™ , Oxygenol™ , Probiotix™ and Maximum Slim™ .






Arthrizyme




Arthrizyme is a systemic oral enzyme designed to revolutionize the way arthritis is naturally treated. According to Time Magazine, we are in the age of arthritis . The Center for Disease Control (CDC) estimates that 1 in 3 Americans have arthritis and/or joint pain. In Canada, 4 million people have been diagnosed with arthritis and millions of others complain of some undiagnosed form of joint pain. Arthrizyme differs from all other natural arthritis remedies. Arthrizyme was designed to work for all types of arthritis and in all joints of the body. Arthrizyme will rid the body of inflammation regardless of location and promote healing. Arthrizyme is fast acting, usually improving symptoms within the first few days.









Digestzyme





DIGESTZYME Bloating, indigestion, heartburn, gas, stomach or intestinal pain are all digestive problems that can be solved with the use of Martin Nutraceuticals Digestzyme. This product was developed with the used of the strongest enzymes available today. Use of this Digestzyme has shown to drastically improve digestion and nutrient absorption.








Oxygenol

Oxygenol is a water soluble, anti-oxidant formula extracted from a particular species of pine bark extract high in bioflavonoids. These bioflavonoids are particularly favorable, due to their nature of blocking unwanted, undesirable compounds in the body.












Heartzyme





HEARTZYME Recent studies and news articles have been reporting some of the exciting new developments in the fight against heart disease. It is now believed that inflammation is the best indicator of heart disease, even better than cholesterol. A simple procedure recommended by the American Heart and Stroke foundation will now be performed as a routine screen for heart disease. This test is called C - reactive protein. C - reactive protein is a chemical necessary for fighting injury and infection and is elevated when inflammation is present. It is now thought that inflammation weakens the fatty build-ups that line the blood vessel walls making them more likely to burst and cause heart attacks. Inflammation also leads to scarring and narrowing of the blood vessels. By measuring C - reactive protein, it will be possible to predict heart disease 10-15 years down the road. Therefore, new treatment consists of taking medications that lower C - reactive protein, thus reducing inflammation. This recent news is truly exciting because many clinical studies have demonstrated that systemic oral enzyme formulas such as Heartzyme lower C - reactive protein. Natural medicine has always touted the benefits of systemic enzyme therapy for heart disease, now allopathic medicine agrees.








Maximum Slim




Maximum Slim is a unique formula that binds fat from food, therefore preventing fat from being absorbed by the body. This in turn suppresses hunger and increases metabolism in a safe and effective way. This weight loss formula consists of capsules, ampoules, a ready-mix drink and a beverage mix. Using the Quick-Start ready mix formula, Martin Nutraceuticals, provides an effective beginning to a healthy weight loss program. Used as a detoxification drink with a consumption of abundant fruits and vegetables, the Quick-Start mix can easily result in a 4-10 pound weight reduction in as short as 2 days.









KEY INVESTMENT HIGHLIGHTS

  • The Martin Nutraceutical Team has been active in contributing to better health care for the past decade. Accumulating a vast knowledge in the naturopathic industry, Martin Nutraceuticals has developed nutraceuticals to help improve the quality of life, in all aspects of life. Implementing the highly coveted success of Dr. Martin's Joint Therapy, which has contributed to helping thousands of people overcome pain and suffering related to arthritis and joint pain, Martin Nutraceuticals has developed a family of innovative complimentary medicine to aid all types of difficulties to enhance a better lifestyle.


  • The Martin Nutraceutical family has expanded to include such revolutionary products such as Arthrizyme™ , Digestzyme™ , Heartzyme™ , Petzyme™ , Oxygenol™ , Maximum Slim and Probiotix™.


  • Systemic oral enzyme therapy is the future of natural medicine. There are well over 160 clinical studies describing the benefits of systemic enzymes on everything from arthritis to heart conditions.




MORE GROUNDBREAKING NEWS






Martin Nutraceuticals Inc. Opens Negotiations to Enter the Australian Market
March 26, 2007






Dr. Tony Martin of Martin Nutraceuticals Inc. Invited to Speak at the Consumer Health Show in Toronto
March 21, 2007






Martin Nutraceuticals Inc. in Negotiations with X Consul Group for Marketing and Distribution Rights of Its Products in Spain and Portugal
March 19, 2007






Martin Nutraceuticals, Inc. Rated 'Speculative Buy,' Target Price $0.13 by Beacon Equity Research
March 16, 2007






Martin Nutraceuticals Announces Commencement of Radio Talk Show Tour
March 7, 2007








For general information on our products, please contact us at:

info@martinnutra.com
10580 N. McCarron Blvd
Suite 115-160
Reno, NV 89503

Toll Free in North America: 1-866-365-6868
Office: (613) 963-0163

If you are interested in contacting investor relations, please contact:

IR@martinnutra.com







This profile is an advertisement; the articles and/or information which appear herein may not be construed as investment advice. All articles, notices, and other information contained herein concerning MNCL is a paid advertisement by a non affiliated third party, which has retained Bridge IR Group, Inc. to produce this advertisement. The information contained herein is based upon sources which we consider reliable but is not guaranteed by OTC Networx or its officers, employees or affiliated partners.

Bridge IR Group, Inc. provides information only, this is not meant to be a recommendation to buy or sell the profiled security, nor is this an offer to buy or sell the security. The publishers of OTC Networx are not investment advisors and are not acting in any way to influence the purchase or sale of the security. Before purchasing or selling any security profiled, it is encouraged and recommended that you consult a stockbroker or other registered financial advisor. The reader must understand that the companies we select involve a high degree of investment risk. Potential investors must understand that they may lose all or a portion of their investment due to the risk involved.

Bridge IR Group, Inc. does not guarantee the accuracy or completeness of the information displayed in the company spotlight section of our web site. By viewing the information displayed in our company spotlight section of our web site you understand that Bridge IR Group, Inc. is not liable for any losses, damages, monetary or otherwise, that may occur due to the content of this profile.

PAST PERFORMANCE MAY NOT BE INDICATIVE OF FUTURE PERFORMANCE

SEC compliance - In order to be in full compliance with the Securities Act of 1933, Sec. 17(b), Bridge IR Group, Inc. has received eleven thousand dollars as compensation from a non affiliated third party. The money received have been accounted for as advertising fees for displaying MNCL corporate information to our visitors/members. Bridge IR Group, Inc. also reserves the right to purchase or sell shares of the company's stock on a voluntary basis in the open market during or after the profiled period. We intend to sell all these shares in the open market.

Information displayed in our company spotlight section of our web site contain forward looking statements within the meaning set forth in Sec. 27 (a) of the Securities Act of 1933 and section 21 (e) of the Securities Exchange Act of 1934. Forward looking statements can be based on estimates, projections, and expectations. These forward looking statements may involve uncertainties and risks.

PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN ANY PROFILED COMPANY.

Invest carefully and avoid internet scams! We encourage you to read the information available at the SEC web site @ http//www.sec.gov and/or the information at the NASD web site @ http://www.nasd.com